Author

S. Kobayashi

h-index 4 View on Semantic Scholar

We have 3 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study.

BACKGROUND The role of a comprehensive genomic profile (CGP) and molecular residual disease (MRD) in circulating tumor DNA (ctDNA) for risk stratification of resectable colorectal oligometastases (CRMs) remains unclear. This study aimed to investigate the feasibility of ctDNA analysis in patients with CRM and to conduc...

S. Kobayashi, T. Takamoto, A. Shiomi et al. · ESMO Open · 0 citations

Sep 2026

Molecular residual disease: Charting a new path for treating resectable solid tumors.

Molecular residual disease (MRD), detected via circulating tumor DNA (ctDNA) after curative-intent surgery, identifies resectable solid tumor patients at high recurrence risk, thereby enabling enriched trials with larger effect sizes and smaller samples. Yet enrichment narrows the eligible population and thus challenge...

S. Kobayashi, T. Hashimoto, H. Bando et al. · Cancer Cell · 0 citations

Review Open access Jul 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...

T. Hashimoto, T. Shibuki, T. Fujisawa et al. · International Journal of Cli... · 0 citations